Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2019

Open Access 01-12-2019 | Idiopathic Pulmonary Fibrosis | Research article

Comparison of disease progression subgroups in idiopathic pulmonary fibrosis

Authors: Miia Kärkkäinen, Hannu-Pekka Kettunen, Hanna Nurmi, Tuomas Selander, Minna Purokivi, Riitta Kaarteenaho

Published in: BMC Pulmonary Medicine | Issue 1/2019

Login to get access

Abstract

Background

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial pneumonia with an unpredictable course. The aims of this study were to retrospectively re-evaluate a cohort of patients with IPF according to the 2011 international IPF guidelines and 1) to characterize the subgroups of patients when classified according to their observed survival times and 2) to evaluate whether Composite Physiologic Index (CPI), Gender-Age-Physiology (GAP) Index or clinical variables could predict mortality.

Methods

Retrospective data was collected and patients were classified into subgroups according to their observed lifespans. Differences in clinical variables, CPI and GAP stages as well as in comorbidities were investigated between the subgroups. Predictors of mortality were identified by COX proportional hazard analyses.

Results

A total of 132 patients were included in this study. The disease course was rapid (≤ 2 years) in 30.0%, moderate (2–5 years) in 28.0% and slow (≥ 5 years) in 29.0% of the patients. Pulmonary function tests (PFT) and CPI at baseline differentiated significantly between the rapid disease course group and those patients with longer survival times. However, the predictive accuracy of the investigated clinical variables was mainly less than 0.80. The proportions of patients with comorbidities did not differ between the subgroups, but more patients with a rapid disease course were diagnosed with heart failure after the diagnosis of IPF. Most patients with a rapid disease course were categorized in GAP stages I and II, but all patients in GAP stage III had a rapid disease course. The best predictive multivariable model included age, gender and CPI. GAP staging had slightly better accuracy (0.67) than CPI (0.64) in predicting 2-year mortality.

Conclusions

Although the patients with a rapid disease course could be differentiated at baseline in terms of PFT and CPI, the predictive accuracy of any single clinical variable as well as CPI and GAP remained low. GAP staging was unable to identify the majority of patients with a rapid disease progression. It is challenging to predict disease progression and mortality in IPF even with risk prediction models.
Literature
1.
go back to reference Kim HJ, Perlman D, Tomic R. Natural history of idiopathic pulmonary fibrosis. Respir Med. 2015;109(6):661–70.PubMedCrossRef Kim HJ, Perlman D, Tomic R. Natural history of idiopathic pulmonary fibrosis. Respir Med. 2015;109(6):661–70.PubMedCrossRef
2.
3.
go back to reference Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167(7):962–9.PubMedCrossRef Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167(7):962–9.PubMedCrossRef
4.
go back to reference Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684–91.PubMedCrossRef Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684–91.PubMedCrossRef
7.
go back to reference Kishaba T, Shimaoka Y, Fukuyama H, Nagano H, Nei Y, Yamashiro S, et al. Clinical characteristics of idiopathic pulmonary fibrosis patients with gender, age, and physiology staging at Okinawa Chubu Hospital. J Thorac Dis. 2015;7(5):843–9.PubMedPubMedCentral Kishaba T, Shimaoka Y, Fukuyama H, Nagano H, Nei Y, Yamashiro S, et al. Clinical characteristics of idiopathic pulmonary fibrosis patients with gender, age, and physiology staging at Okinawa Chubu Hospital. J Thorac Dis. 2015;7(5):843–9.PubMedPubMedCentral
8.
go back to reference Kishaba T, Nagano H, Nei Y, Yamashiro S. Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status. J Thorac Dis. 2016;8(6):1112–20.PubMedPubMedCentralCrossRef Kishaba T, Nagano H, Nei Y, Yamashiro S. Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status. J Thorac Dis. 2016;8(6):1112–20.PubMedPubMedCentralCrossRef
9.
go back to reference Kakugawa T, Sakamoto N, Sato S, Yura H, Harada T, Nakashima S, et al. Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis. Respir Res. 2016;17(1):79.PubMedPubMedCentralCrossRef Kakugawa T, Sakamoto N, Sato S, Yura H, Harada T, Nakashima S, et al. Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis. Respir Res. 2016;17(1):79.PubMedPubMedCentralCrossRef
11.
go back to reference Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Nair A, Karwoski R, et al. Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures. Eur Respir J. 2017;49(1). https://doi.org/10.1183/13993003.01011. Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Nair A, Karwoski R, et al. Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures. Eur Respir J. 2017;49(1). https://​doi.​org/​10.​1183/​13993003.​01011.
12.
go back to reference Fisher JH, Al-Hejaili F, Kandel S, Hirji A, Shapera S, Mura M. Multi-dimensional scores to predict mortality in patients with idiopathic pulmonary fibrosis undergoing lung transplantation assessment. Respir Med. 2017;125:65–71.PubMedCrossRef Fisher JH, Al-Hejaili F, Kandel S, Hirji A, Shapera S, Mura M. Multi-dimensional scores to predict mortality in patients with idiopathic pulmonary fibrosis undergoing lung transplantation assessment. Respir Med. 2017;125:65–71.PubMedCrossRef
13.
go back to reference Sugino K, Shimizu H, Nakamura Y, Isshiki T, Matsumoto K, Homma S. Clinico-radiological features and efficacy of anti-fibrotic agents in atypical idiopathic pulmonary fibrosis. J Thorac Dis. 2018;10(2):899–908.PubMedPubMedCentralCrossRef Sugino K, Shimizu H, Nakamura Y, Isshiki T, Matsumoto K, Homma S. Clinico-radiological features and efficacy of anti-fibrotic agents in atypical idiopathic pulmonary fibrosis. J Thorac Dis. 2018;10(2):899–908.PubMedPubMedCentralCrossRef
14.
go back to reference Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.PubMedPubMedCentralCrossRef Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.PubMedPubMedCentralCrossRef
15.
go back to reference Karkkainen M, Kettunen HP, Nurmi H, Selander T, Purokivi M, Kaarteenaho R. Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis. Respir Res. 2017;18(1):160.PubMedPubMedCentralCrossRef Karkkainen M, Kettunen HP, Nurmi H, Selander T, Purokivi M, Kaarteenaho R. Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis. Respir Res. 2017;18(1):160.PubMedPubMedCentralCrossRef
18.
go back to reference Viljanen AA, Halttunen PK, Kreus KE, Viljanen BC. Spirometric studies in non-smoking, healthy adults. Scand J Clin Lab Invest Suppl. 1982;159:5–20.PubMedCrossRef Viljanen AA, Halttunen PK, Kreus KE, Viljanen BC. Spirometric studies in non-smoking, healthy adults. Scand J Clin Lab Invest Suppl. 1982;159:5–20.PubMedCrossRef
20.
go back to reference Hyldgaard C, Hilberg O, Muller A, Bendstrup E. A cohort study of interstitial lung diseases in central Denmark. Respir Med. 2014;108(5):793–9.PubMedCrossRef Hyldgaard C, Hilberg O, Muller A, Bendstrup E. A cohort study of interstitial lung diseases in central Denmark. Respir Med. 2014;108(5):793–9.PubMedCrossRef
21.
go back to reference Soares Pires F, Caetano Mota P, Melo N, Costa D, Jesus JM, Cunha R, et al. Idiopathic pulmonary fibrosis--clinical presentation, outcome and baseline prognostic factors in a Portuguese cohort. Rev Port Pneumol. 2013;19(1):19–27.PubMedCrossRef Soares Pires F, Caetano Mota P, Melo N, Costa D, Jesus JM, Cunha R, et al. Idiopathic pulmonary fibrosis--clinical presentation, outcome and baseline prognostic factors in a Portuguese cohort. Rev Port Pneumol. 2013;19(1):19–27.PubMedCrossRef
22.
go back to reference King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001;164(7):1171–81.PubMedCrossRef King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001;164(7):1171–81.PubMedCrossRef
23.
go back to reference Kim JH, Lee JH, Ryu YJ, Chang JH. Clinical predictors of survival in idiopathic pulmonary fibrosis. Tuberc Respir Dis (Seoul). 2012;73(3):162–8.CrossRef Kim JH, Lee JH, Ryu YJ, Chang JH. Clinical predictors of survival in idiopathic pulmonary fibrosis. Tuberc Respir Dis (Seoul). 2012;73(3):162–8.CrossRef
24.
go back to reference Lee SH, Kim SY, Kim DS, Kim YW, Chung MP, Uh ST, et al. Predicting survival of patients with idiopathic pulmonary fibrosis using GAP score: a nationwide cohort study. Respir Res. 2016;17(1):131.PubMedPubMedCentralCrossRef Lee SH, Kim SY, Kim DS, Kim YW, Chung MP, Uh ST, et al. Predicting survival of patients with idiopathic pulmonary fibrosis using GAP score: a nationwide cohort study. Respir Res. 2016;17(1):131.PubMedPubMedCentralCrossRef
25.
go back to reference Ley B, Bradford WZ, Vittinghoff E, Weycker D, du Bois RM, Collard HR. Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;194(6):711–8.PubMedPubMedCentralCrossRef Ley B, Bradford WZ, Vittinghoff E, Weycker D, du Bois RM, Collard HR. Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;194(6):711–8.PubMedPubMedCentralCrossRef
26.
go back to reference Romei C, Tavanti L, Sbragia P, De Liperi A, Carrozzi L, Aquilini F, et al. Idiopathic interstitial pneumonias: do HRCT criteria established by ATS/ERS/JRS/ALAT in 2011 predict disease progression and prognosis? Radiol Med. 2015;120(10):930–40.PubMedCrossRef Romei C, Tavanti L, Sbragia P, De Liperi A, Carrozzi L, Aquilini F, et al. Idiopathic interstitial pneumonias: do HRCT criteria established by ATS/ERS/JRS/ALAT in 2011 predict disease progression and prognosis? Radiol Med. 2015;120(10):930–40.PubMedCrossRef
27.
go back to reference Yamauchi H, Bando M, Baba T, Kataoka K, Yamada Y, Yamamoto H, et al. Clinical course and changes in high-resolution computed tomography findings in patients with idiopathic pulmonary fibrosis without honeycombing. PLoS One. 2016;11(11):e0166168.PubMedPubMedCentralCrossRef Yamauchi H, Bando M, Baba T, Kataoka K, Yamada Y, Yamamoto H, et al. Clinical course and changes in high-resolution computed tomography findings in patients with idiopathic pulmonary fibrosis without honeycombing. PLoS One. 2016;11(11):e0166168.PubMedPubMedCentralCrossRef
28.
go back to reference Kim H, Gillen K, Tomic R. Idiopathic pulmonary fibrosis: typical versus atypical survival characteristics. Am J Respir Crit Care Med. 2013;187:A4333.CrossRef Kim H, Gillen K, Tomic R. Idiopathic pulmonary fibrosis: typical versus atypical survival characteristics. Am J Respir Crit Care Med. 2013;187:A4333.CrossRef
29.
go back to reference Gribbin J, Hubbard R, Smith C. Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. Respir Med. 2009;103(6):927–31.PubMedCrossRef Gribbin J, Hubbard R, Smith C. Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. Respir Med. 2009;103(6):927–31.PubMedCrossRef
30.
go back to reference Hyldgaard C, Hilberg O, Bendstrup E. How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir Med. 2014;108(4):647–53.PubMedCrossRef Hyldgaard C, Hilberg O, Bendstrup E. How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir Med. 2014;108(4):647–53.PubMedCrossRef
31.
go back to reference Mura M, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J. 2012;40(1):101–9.PubMedCrossRef Mura M, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J. 2012;40(1):101–9.PubMedCrossRef
Metadata
Title
Comparison of disease progression subgroups in idiopathic pulmonary fibrosis
Authors
Miia Kärkkäinen
Hannu-Pekka Kettunen
Hanna Nurmi
Tuomas Selander
Minna Purokivi
Riitta Kaarteenaho
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2019
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-019-0996-2

Other articles of this Issue 1/2019

BMC Pulmonary Medicine 1/2019 Go to the issue